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For many years there has been confusion about
what the levels in the Food and Drug
Administration’s (FDA) Inactive Ingredient
Database (IID) actually mean. The excipient
levels listed in this database under "Maximum
Potency" are the levels that has been approved
by the FDA in, at least one product, for a
specific route of administration and dosage
form.  However, the levels listed in the IID are
simply the maximum levels that was approved
on a per dose basis! This establishes a
precedence of use (per dose) for a particular
route of administration that can be referenced
when assessing excipient safety in drug
applications. What matters for an excipient,
when referencing a maximum potency in an
Abbreviated New Drug Application (ANDA),
is the highest level listed in the IID for a
particular route of administration, not
necessarily a particular dosage form. For
example the highest level for any oral dosage
form can be used to justify a level for any other
oral dosage form. However, these levels are not
necessarily the maximum daily intake levels that
were approved which is an important
distinction.  
This causes confusion, particularly for generic
companies because they must reference both
the maximum potency in the IID and a
maximum daily intake (MDI) level in their
ANDAs to show that they do not exceed what
has been used on a per day level of a specific
excipient in a previously approved product.
There is no database available at this time,
accessible to either the public or the FDA,
which includes information on the maximum
daily intake level. All that is available is the IID,
which only gives the approved, per dose levels,
for different routes of administration.
However, what it does not provide for a given
excipient is, whether the approved drug which
resulted in the maximum "per dose" level was
dosed multiple times or only once per day. This
causes the confusion prevalent today, especially
in the generic industry. *
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This situation creates a major data gap for the
FDA as well. Currently there is no easy way to
find out whether a maximum daily intake level
is higher than what is listed in the IID for one
dose. As a result many formulation scientists
use the IID level as if it was the maximum daily
intake level because they know that this is
"safe" from a regulatory perspective.
Unfortunately, in many cases, this approach can
result in a poor formulation, that is only "good
enough" to be approved but not necessarily be
the best formulation that could be developed
from a quality, performance and/or manu-
facturability perspective had greater levels of
some excipients been used.
Instead of using QbD to develop drugs in these
cases, consider this a Quality by IID Limitation
(QbIL), which is counterproductive if the aim is
to improve product quality, performance and
consistency and move towards more advanced
manufacturing methods and better products
designed for specific target populations, such
as, pediatrics. Unfortunately, this is what a
number of generic companies actually do when
they develop their formulations. They are
reluctant to explore what they could possibly
use in their formulations, without regulatory
issues, because it takes significant time to assess
and get the correct MDI information for a
given excipient for a specific route of
administration.
Currently, the only way a company can find out
if an excipient level, higher than the IID level,
would be acceptable when filing an ANDA, is
for them to submit a control led
correspondence with the FDA with a request
for the FDA to research the maximum daily
intake levels for a particular, previously
approved excipient, to find if the desired level
they want to use is below an approved MDI
level. It typically takes the FDA several months
to respond since they can only determine the
levels through manual research within their
existing systems involving significant time and
effort. In many cases, this type of delay can
impact a generic company's filing and approval
date which can have huge implications,
especially in first to file situations. 
The only other alternative for a generic
company is to submit detailed toxicology data
on the specific excipient to justify its level of
use. However, this may also result in significant
delays during the review process. It can also
increase the risk of receiving a Refuse to
Receive (RTR) notice at the time of filing
should there be any disagreement on the type
of data that should have been supplied.
IPEC-Americas has been working with the
FDA since December 2011 to improve the IID
and the policies that the FDA utilizes to
determine IID Maximum Potency levels in
ANDAs. The Generic Pharmaceutical
Association (GPhA) is now also involved with
this team. Currently, how the FDA handles the
policies concerning the IID internally is, unclear
at best, resulting in a number of RTR
notifications that may be unnecessary. Progress
has been made but it has been slow going so far
due to the implementation of the Generic Drug
User Fee Amendments of 2012 (GDUFA) and
reorganization at the FDA Office of
Pharmaceutical Quality over the last few years.
That said, progress has been made behind the
scenes and it is hoped that improvements will
begin to show up in the near future.  
The FDA is developing a new database for
inactive ingredients which will include
information on the MDI levels. The biggest
part of this will be researching, currently done
manually and, verifying the MDI levels for each
route of administration. There has also been
discussions about possible benefits of
including, in the future, MDI levels for
pediatric use. The FDA plans to use some of
the resources they have acquired under
GDUFA to carry out this research.
IPEC-Americas will continue to actively work
with the FDA on this project and is expected to
present on this topic at a future joint AAPS and
FDA webinar.
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The following are some of the key issues
identified by IPEC-Americas that still need to
be addressed:
< The IID was not updated between September
2013 and May 2015. Many excipients and the
levels used in drug products which were
approved during this time were not entered into
the IID. Additionally, there are a number of
cases of inaccurate information and
non-standardized names included in the current
IID. Some levels are incorrect since they do not
appear to be traceable to an actual approved
drug which used the listed level. The FDA is
committed to verifying all IID levels to establish
accuracy and traceability.
< There are unclear requirements for how
“families” of materials (e.g. Hypromelloses,
Polyethylene Oxides, Silicones, Carbomers, etc.)
should be handled and what data is needed to
support safe use levels in ANDAs. Many
discussions on this topic are ongoing since this
issue has created many unjustified RTRs.
< The maximum potency levels that are listed in
percentages cannot be converted to any type of
weight per dose and are basically worthless for
referencing in an ANDA. The FDA is aware of
this and essentially cannot utilize this
information when comparing any levels in other
drugs. They intend to eliminate all these
references in the future as they clean up the IID
because these % levels have caused a lot of
confusion and have resulted in a number of
RTRs for ANDAs. In the future, the FDA hopes
to convert some of the % information to
milligrams if they can connect the IID listing to
an actual application where they can find out the
actual maximum per dose level in milligrams.
< It is still not possible to identify the maximum
daily intake of ingredients required for ANDAs. 
This cannot be resolved until the FDA launches
a new IID database.
< There is a lot of confusion regarding the Refuse
to  Rece ive  (RTR)  and Contro l l ed
Correspondence Guidances which actually
conflict with what has already been agreed to
between the FDA IID Expert Working Group
(EWG) and the IPEC-Americas IID Team.
These guidances need to be revised based on the
ongoing discussions.
The IPEC-Americas IID Team (including a
representative from GPhA) coordinated special
meetings in December, 2014 and July, 2015
with personnel responsible for FDA policy and
toxicology to try to accelerate progress on a
number of these issues. IPEC-Americas
presented strong scientific support for the
family approach and requested that the FDA
make a decision on this issue as soon as
possible. Another meeting is planned with the
FDA on September 18, 2015 where a number
of topics, including the family approach, will be
discussed.
Most recently, the FDA updated the Inactive
Ingredient Database (IID) in May, 2015 and
again on August 12, 2015. The August revision
was the second update that FDA has done to
try to "clean-up" the IID database and make
sure that the information in the database can be
traced to an actual approved drug application
for a specific route of administration and
dosage form.  
Many changes have been made to the IID
resulting in some of the names being changed
to preferred nomenclature, as well as, changes
to the maximum potency levels, increasing or
decreasing from the previous listed levels based
on the FDA's ongoing verification process. In
some cases certain names or references have
been removed completely from the IID or
significantly renamed creating a number of
questions throughout the industry.
The FDA is still working on this IID
"clean-up" process and is expected to make
additional changes to the IID in October, 2015.
If you need to use the IID you should search
the IID database, as soon as possible, to
evaluate the listings for the materials that may
have changed. The IPEC-Americas IID Team
will be discussing the August 12th changes with
FDA during a meeting scheduled for
September 18, 2015. The minutes from this
meeting, together with the minutes from all
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previous meetings, will be posted on the FDA
website (1). 
IPEC-Americas will continue to work with the
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